Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Subjects

Next Previous
Trial Profile

A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REGN5713-5714-5715 (Primary) ; REGN5713-5714-5715 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 11 Jun 2021 Primary endpoint (Change in area under curve for TNSS over the first hour (0-1hr) from the screening NAC challenge to the day 8 challenge) has been met as per results published in the Journal of Allergy and Clinical Immunology
  • 11 Jun 2021 Results published in the Journal of Allergy and Clinical Immunology
  • 24 Apr 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top